CD274 and intrahepatic cholangiocarcinoma: According to clinical data presented at the 2018 European Society of Internal Oncology (ESMO) congress, M7824 has an overall response rate (ORR) of 20% in patients with ICC who have failed first-line treatment and is not affected by PD-L1 level (response duration of 8.3–13.9 months), and has been granted orphan drug status by FDA for cholangiocarcinoma.